Nat Med. 2025 Jan 21. IF: 58.7
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial.
www.nature.com/articles/s41591-024-03415-7
Nat Med. 2025 Jan 21. IF: 58.7
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.
www.nature.com/articles/s41591-024-03414-8
J Clin Oncol. 2025 Jan 21. IF: 42.1
Timely Reporting of Patient-Reported Outcomes in Cancer Clinical Trials: An Ethical Imperative.
www.ascopubs.org/doi/10.1200/JCO-24-02021
Cancer Discov. 2025 Jan 21. IF: 29.7
Bone-Induced Her2 Promotes Secondary Metastasis in HR+/Her2- Breast Cancer.
www.aacrjournals.org/cancerdiscovery/article/751165
Nat Immunol. 2025 Jan 21. IF: 27.7
Cholesterol mobilization regulates dendritic cell maturation and the immunogenic response to cancer.
www.nature.com/articles/s41590-024-02065-8
Nat Cancer. 2025 Jan 21. IF: 23.5
Targeting BRCA1-deficient PARP inhibitor-resistant cells with nickases reveals nick resection as a cancer vulnerability.
www.nature.com/articles/s43018-024-00902-1
Adv Sci (Weinh). 2025 Jan 21. IF: 14.3
Secernin-2 Stabilizes Histone Methyltransferase KMT2C to Suppress Progression and Confer Therapeutic Sensitivity to PARP Inhibition in Triple-Negative Breast Cancer.
www.onlinelibrary.wiley.com/doi/10.1002/advs.202413280
J Exp Clin Cancer Res. 2025 Jan 20;44(1):19. IF: 11.4
CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.
www.biomedcentral.com/articles/10.1186/s13046-025-03276-z
JAMA Netw Open. 2025 Jan 2;8(1):e2455383. IF: 10.5
External Validation of a 5-Factor Risk Model for Breast Cancer-Related Lymphedema.
www.jamanetwork.com/journals/jamanetworkopen/fullarticle/2829416
